ERBB2 and breast cancer: The Danish Breast Cancer Cooperative group collected and tested a consecutive hormone receptor-positive, HER2-negative cohort with PAM50, and concluded that the 10-year prognostic prediction is helpful in identifying those patients who can spare chemotherapy [48].